A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher‐risk myelodysplastic syndrome

• Published in: Cancer Vol. 118; no. 3; pp. 722 - 728
• Main Authors: Faderl, Stefan, Garcia‐Manero, Guillermo, Jabbour, Elias, Ravandi, Farhad, Borthakur, Gautam, Estrov, Zeev, Gandhi, Varsha, Byrd, Anna L., Kwari, Monica, Cortes, Jorge, Kantarjian, Hagop M.
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.02.2012; Wiley-Blackwell
• Subjects: Adenine Nucleotides - administration & dosage; Adult; Aged; Aged, 80 and over; Antineoplastic Agents - administration & dosage; Arabinonucleosides - administration & dosage; Biological and medical sciences; clofarabine; Cohort Studies; DNA methyltransferase inhibitors; Drug Administration Schedule; Female; Hematologic and hematopoietic diseases; Humans; Injections, Intravenous; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Male; Medical sciences; Middle Aged; myelodysplastic syndrome; Myelodysplastic Syndromes - drug therapy; Myelodysplastic Syndromes - mortality; nucleoside analogs; Remission Induction; Risk Factors; Survival Rate; Treatment Outcome; Tumors; Antineoplastic agent; Human; Intravenous administration; DNA methyltransferase inhibitors; Malignant hemopathy; Clofarabine; Myelodysplastic syndrome; Randomization; Cancerology; Treatment; nucleoside analogs; Antimetabolic; Risk factor; Nucleoside analog; Inhibitor; Dose; Cancer

BACKGROUND: Clofarabine is a nucleoside analog with activity in myeloid malignancies. Experience in myelodysplastic syndrome (MDS) is limited. METHODS: The goal of this study was to evaluate the activity and safety of 2 different doses (15 mg/m2 vs 30 mg/m2 daily × 5 days) of intravenous clofarabine...